U.S. Physical Therapy (NYSE:USPH) issued an update on its FY18 earnings guidance on Thursday morning. The company provided EPS guidance of $2.50-2.57 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.52.
NYSE:USPH opened at $113.00 on Friday. The firm has a market cap of $1.36 billion, a PE ratio of 47.58, a P/E/G ratio of 3.81 and a beta of 1.19. The company has a quick ratio of 2.06, a current ratio of 2.06 and a debt-to-equity ratio of 0.27. U.S. Physical Therapy has a fifty-two week low of $64.45 and a fifty-two week high of $129.65.
U.S. Physical Therapy (NYSE:USPH) last released its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.06. U.S. Physical Therapy had a return on equity of 13.81% and a net margin of 5.03%. The firm had revenue of $113.10 million during the quarter, compared to the consensus estimate of $112.79 million. U.S. Physical Therapy’s revenue was up 9.8% on a year-over-year basis. On average, research analysts expect that U.S. Physical Therapy will post 2.53 earnings per share for the current year.
The firm also recently declared a dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 9th will be issued a dividend of $0.23 per share. The ex-dividend date is Thursday, November 8th. U.S. Physical Therapy’s dividend payout ratio (DPR) is currently 44.23%.
A number of equities analysts have recently commented on USPH shares. Zacks Investment Research raised U.S. Physical Therapy from a hold rating to a buy rating and set a $129.00 price target for the company in a report on Tuesday, August 7th. Jefferies Financial Group reissued a hold rating and set a $105.00 price target on shares of U.S. Physical Therapy in a report on Friday, August 3rd. Barrington Research reissued a hold rating on shares of U.S. Physical Therapy in a report on Friday, August 3rd. Finally, Cantor Fitzgerald boosted their price target on U.S. Physical Therapy from $103.00 to $107.00 and gave the stock a neutral rating in a report on Friday. Four investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. U.S. Physical Therapy currently has a consensus rating of Buy and an average target price of $113.67.
In other U.S. Physical Therapy news, Director Mark J. Brookner sold 2,500 shares of the company’s stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $116.00, for a total value of $290,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Clayton Trier sold 1,250 shares of the company’s stock in a transaction dated Friday, August 17th. The stock was sold at an average price of $115.50, for a total value of $144,375.00. The disclosure for this sale can be found here. Insiders have sold a total of 22,750 shares of company stock valued at $2,642,402 in the last three months. 2.50% of the stock is owned by insiders.
About U.S. Physical Therapy
U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.
Read More: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.